Navigation Links
Helix BioPharma Announces Q3 2009 Financial Results and Provides Product Development Update
Date:6/15/2009

ng negative findings or factors that may become apparent during the course of research or development which may result in the discontinuation or delay of the research or development projects; the risk of technical obsolescence; the need for further regulatory approvals, which may not be obtained in a timely matter or at all; intellectual property risks, including without limitation, the risk that three patents for Topical Interferon Alpha-2b will expire in 2013 and no additional patent may be issued; marketing/manufacturing and partnership/strategic alliance risks; the need to further upscale the manufacturing process for the Company's drug candidates and the risk that further upscaling may not be achieved within the timelines expected by the Company or at all; the effect of competition; uncertainty of the size and existence of a market opportunity for Helix's products; Helix's dependence on its contractors, consultants, advisors and licensees, including without limitation, contract research organizations, contract manufacturing organizations, clinical trial consultants, collaborative research consultants, regulatory affairs advisors, and others, whose performance and interdependence can critically affect the Company's performance and the achievement of its milestones; the risk that the Company's license optionee for Topical Interferon Alpha-2b may not continue to provide the Company with interferon alpha-2b or exercise its option, which would have a negative effect on the further development of the drug candidate and on the Company; Helix's dependence on its licensor of the L-DOS47 antibody; the need to secure new strategic relationships, which is not assured, to commercialize L-DOS47 and any other drug candidates which may arise out of DOS47; the Company's dependence on a few customers and a few suppliers, the loss of any of which would negatively impact the Company's operations; the risk of unanticipated expenses or unanticipated reductions in revenue, or both;
'/>"/>
SOURCE Helix BioPharma Corp.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related biology technology :

1. Helix Biopharma announces addition of University of Arizona professor Kenneth Hatch as new medical advisor
2. Helix BioPharma Chairman resigns
3. Helix BioPharma Corp. announces fiscal 2007 results
4. Helix BioPharma Corp. announces management changes
5. Helix BioPharma announces $16.9 million private placement of common shares
6. Helix BioPharma announces Q1 2008 financial results
7. Helix BioPharma closes $16.9 million private placement of common shares
8. Helix BioPharma Corp. contracts KBI Biopharma to develop an L-DOS47 clinical packaging format
9. Helix BioPharma shareholders vote in favour of management
10. Helix BioPharma reports Q2 2008 highlights, financial results
11. W. Thomas Hodgson appointed to board of Helix BioPharma Corp.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... 20, 2014 Earle Martin ... announced today that Ellen Teplitzky, an experienced attorney ... the pharmaceutical industry, has joined the firm as ... legal services practice. NDA Partners provides legal ... and testimony, to top law firms and their ...
(Date:10/19/2014)... October 20, 2014 OCTOBER ... Meeting (ABIM). ABIM will take place ... information about ABIM 2014 is now available ... Delegates representing companies and organizations from all ... obtain information on the latest products and ...
(Date:10/19/2014)... The Asian Automatic patient billing report defines ... forecast of revenue. The Automatic patient billing market in ... by 2018, at a developing CAGR of 7.2% from ... the Asian Automatic patient billing market, to get an ... a glimpse of the segmentation of this market in ...
(Date:10/19/2014)... The Asian Orthopedic braces and support systems report defines ... forecast of revenue. The Orthopedic braces and support systems market ... by 2018, at a developing CAGR of 4.4% from 2013 ... Orthopedic braces and support systems market, to get an idea ... of the segmentation of orthopedic braces and support systems market ...
Breaking Biology Technology:NDA Partners Appoints Ellen Teplitzky, JD as Director of its Legal Services Practice 2The Asian Automatic patient billing market is estimated to grow to around $463.9 million by 2018 - New Report by MicroMarket Monitor 2The Asian Automatic patient billing market is estimated to grow to around $463.9 million by 2018 - New Report by MicroMarket Monitor 3The Asian Orthopedic braces and support systems market is estimated to grow to around $416.5 million by 2018 - New Report by MicroMarket Monitor 2The Asian Orthopedic braces and support systems market is estimated to grow to around $416.5 million by 2018 - New Report by MicroMarket Monitor 3The Asian Orthopedic braces and support systems market is estimated to grow to around $416.5 million by 2018 - New Report by MicroMarket Monitor 4
... DIEGO, July 24 /PRNewswire-FirstCall/ - MIGENIX Inc.,(TSX: MGI; ... infectious,diseases, advises that the directors of MIGENIX Inc. ... to be held at 2:00 p.m. (Vancouver,time) on ... Sciences Mall, Vancouver,British Columbia. Further details with respect ...
... ITMN ) announced today that it will release second ... Thursday, July 31, 2008,at 4:00 p.m. Eastern time. A ... at 4:30 p.m. Eastern time that same day., ... (international), conference ID# 57393097. To access the,webcast, please log ...
... LEXINGTON, Mass., July 24 Instrumentation Laboratory,(IL) today ... services,company, has awarded the Company with a five-year ... based in Dallas, TX, counts,among its clients more ... care facilities and more than 18,000 physician practices., ...
Cached Biology Technology:InterMune to Release Second Quarter 2008 Financial Results and Provide Business Update on July 31 2Instrumentation Laboratory Announces Contract for Multi-Parameter Testing Products with Broadlane 2
(Date:10/18/2014)... suspected genetic conditions, a certain type of exome sequencing ... than traditional molecular diagnostic methods, according to a study ... released to coincide with the American Society of Human ... protein­coding region of the genome (the complete set of ... organism), has been rapidly applied in research settings and ...
(Date:10/17/2014)... release is available in German . ... a very few drugs. When treating overdoses, doctors are often ... especially difficult if there is a combination of drugs involved. ... and accidentally swallows his grandmother,s pills? ETH professor Jean-Christophe Leroux ... to find an answer to this question. "The task was ...
(Date:10/16/2014)... researchers have challenged conventional thinking on how the bowel ... mechanism for how bowel cancer starts. , The researchers ... and regenerating the ,crypts, that are a feature of ... involved in bowel cancer development, a controversial finding as ... , Using 3D imaging technologies, Dr Chin Wee Tan ...
Breaking Biology News(10 mins):Study examines type of exome sequencing and molecular diagnostic yield 2Study examines type of exome sequencing and molecular diagnostic yield 3Emergency aid for overdoses 2Emergency aid for overdoses 3Cryptic clues drive new theory of bowel cancer development 2
... States, smart growth proponents have urged communities to cluster ... and familiar sprawl. Cluster developments create a far ... of the land area than dispersed houses. The ... space, farmland, and rural character. Yet few studies ...
... up to an undergraduate class, being given a dissertation ... improve on it. This was the experience ... London,s) Department of Science and Technology Studies between 2000 ... teaching is a full-blown academic monograph published this month ...
... stories of shepherds and travellers encountering lions, for example ... on flocks and people by these fierce predators. Lions ... but for livestock owners around the Waza National Park, ... loss of human life is rarely reported, lion predation ...
Cached Biology News:Location, location, location 2Location, location, location 3Living with lions 2
NATIVE RAT OSTEOCALCIN...
Form: Ready to use Applications: Immunohistology-frozen, Immunohistology-paraffin, Western Blot, ELISA...
Form: Ready to use Applications: ELISA...
EnzChek Ultra Xylanase Assay Kit *500 assays*...
Biology Products: